ISIS Financial Facts

Licensing and royalty revenue: 265K
Gain (loss) on investments, net: 538K
See Full Income Statement

Long-term deferred contract revenue: 110.61M
Deposits and other assets: 4.53M
See Full Balance Sheet

Isis Pharmaceuticals, Inc. (ISIS) Earnings

  |   Expand Research on ISIS
Next EPS Date 3/2/15 *Est. EPS Growth Rate -9.5% *Last Qtr.
Average EPS % Beat Rate -9.8% Revenue Growth Rate +86.9% *Last Qtr.
Average % Move 1-Wk after EPS +2.9% Normal Earnings Time Before Open
Date  Qtr EPS Cons. Surprise Revs Cons. Gd. 1-Week % 1-Day % Details
2/28/11 Q410 -$0.14-$0.22 +$0.08$26.4M$22.55M N/A Details
5/5/11 Q111 -$0.20-$0.19 -$0.01$21.1M$25.69M N/A Details
8/4/11 Q211 -$0.18-$0.22 +$0.04$24.8M$23.98M N/A Details
11/7/11 Q311 -$0.27-$0.20 -$0.07$20.7M$25.33M N/A Details
2/29/12 Q411 -$0.20-$0.18 -$0.02$32.4M$30.3M N/A Details
5/8/12 Q112 -$0.24-$0.26 +$0.02$23.2M$22.72M N/A Details
8/6/12 Q212 -$0.01-$0.10 +$0.09$47.3M$40.06M N/A Details
11/6/12 Q312 -$0.37-$0.26 -$0.11$11.6M$23.11M N/A Details